I agree with jq1234 that Nexavar has been remarkably consistent across trials in PFS. In addition this trial is a homogeneous group of patients.
So I also take this as bullish for Aveo - I think this is a distinctly unappreciated stock as I believe it is going to be the drug of choice for VEGF combo therapy.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.